Table 2.
Parameter estimates for meropenem from the final covariate two-compartment population pharmacokinetic model
| Parameter | ACLF | NLF | p |
|---|---|---|---|
| Structural pharmacokinetic parameters for meropenem (RSE, %) | |||
| CL [L/h] | 5.06 (6.70) | ns | |
| V1 [L] | 8.31a | n/a | |
| V2 [L] | 35.5 (33.3) | 18.5 (33.2) | 0.05 |
| Q [L/h] | 7.23 (9.80) | n/a | |
| Interindividual variability parameters for meropenem (RSE, %) | |||
| CL, CV [%] | 29.8 (16.8) | n/a | |
| Q, CV [%] | 27.6 (28.8) | n/a | |
| Residual variability parameter σ proportional, CV % | 22.0 (8.40) | n/a | |
RSE is presented on the approximated standard deviation scale
ACLF acute-on-chronic liver failure, NLF patients without liver failure, CL clearance, V1/2 central/peripheral volume of distribution, Q intercompartmental clearance, CV coefficient of variation, ns not statistically significant, n/a not applicable, RSE relative standard error
aValue fixed (see “Methods” section)